清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

POS0271 INFLIXIMAB FOR PARENCHYMAL NEURO-BEHÇET’S SYNDROME: A META-ANALYSIS

英夫利昔单抗 医学 病理 疾病
作者
Wenjie Zheng,Xiao Wang,Yan Liu,Yiyuan Ao,Jinling Wang,J. Liu,Yan Xu
标识
DOI:10.1136/annrheumdis-2024-eular.2748
摘要

Background:

Behçet's syndrome (BS) is a chronic, recurrent systemic vasculitis that can affect multiple systems. Neuro-Behçet's syndrome (NBS), especially parenchymal NBS(p-NBS), results in severe neurological sequelae with poor prognosis, ranging from cognitive changes to paralysis, which remains a challenging clinical issue.

Objectives:

This study aimed to evaluate the efficacy and safety of infliximab (IFX), a type of anti-TNF-α agents, in treating patients with p-NBS and hopefully provide a detailed time analysis for the IFX effect timeline in NBS treatment.

Methods:

We conducted this meta-analysis following the PRISMA guidelines. PubMed, Embase, Cochrane Library and Web of Science were systematically searched using the following logics: Behçet's syndrome (all synonyms) AND Infliximab (all synonyms) AND ('neuro' OR 'neurological' OR 'neurologic), and we also included the data from our institution in this meta-analysis. Therapeutic efficacy was evaluated by the improvement of clinical symptoms and radiological lesions, and clinical improvement was specifically defined as complete remission (CR), partial remission (PR) and no response (NR) [1,2]. We evaluated the efficacy of IFX at 3, 6, and 12 months respectively. The results were presented as forest plots with 95% confidence intervals. Besides, the details of adverse drug reactions were recorded.

Results:

8 studies involving a total of 77 patients were identified to perform the meta-analysis by adding the results from our institution. The pooled efficacy of IFX in treating p-NBS patients were analyzed. Clinical complete remission was achieved in 14.7% (95%CI 0.00-83.5%) of patients at Month 3, 28.7% (95% CI 0.00-86.7%) of patients at Month 6, 54.4% (95%CI 13.9-92.3%) at Month 12. Clinical partial remission was achieved in 97.0% (95%CI 61.9-100%) of patients at Months 3, 89.6% (95%CI 45.9-100%) of patients at Months 6, 100.0% (95%CI 96.0-100%) at Months 12. MRI improvement was achieved in 100.0% (95%CI 89.7-100%) of patients at Month 3, 89.1% (95% CI 26.3-100%) of patients at Month 6, 99.5% (95% CI 96.0-100%) at Month 12. The time-phase analysis indicated that IFX exerted its effect within 3 months and was sustained during the long term. Safety information was reported in 16 patients. Among them, 9% of patients experienced severe adverse events (AEs), no AE-related deaths were reported.

Conclusion:

IFX is an effective treatment option for p-NBS, and the incidence of severe AEs was acceptable. A comprehensive evaluation should be performed after three months of medication to determine the need for adjustments in subsequent therapy. Further well-designed, large-scale RCTs are needed to verify our findings.

REFERENCES:

[1] Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863. [2] Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behçet's disease: A case series and review of the literature. Arthritis Care and Research 2008;59:285-90. (Article).

Acknowledgements:

We thank all the participants and their families.

Disclosure of Interests:

None declared.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
berry完成签到,获得积分10
2秒前
Jasonkun完成签到,获得积分10
3秒前
alee完成签到,获得积分10
4秒前
jlin完成签到,获得积分10
13秒前
豆豆完成签到,获得积分10
14秒前
能干念波完成签到 ,获得积分10
16秒前
muriel完成签到,获得积分0
16秒前
17991完成签到,获得积分10
19秒前
彩色的芷容完成签到 ,获得积分10
19秒前
creep2020完成签到,获得积分0
26秒前
冷静的尔竹完成签到,获得积分10
28秒前
Morrow完成签到,获得积分10
33秒前
e746700020完成签到,获得积分10
37秒前
珈沐完成签到,获得积分10
37秒前
多情敏完成签到,获得积分10
42秒前
开关盒完成签到,获得积分10
44秒前
1分钟前
文艺的纸鹤完成签到,获得积分10
1分钟前
1分钟前
明朗完成签到 ,获得积分10
1分钟前
丰富的从雪完成签到,获得积分10
1分钟前
正常糖完成签到 ,获得积分10
2分钟前
舒服的月饼完成签到 ,获得积分10
2分钟前
腼腆的山兰完成签到 ,获得积分10
2分钟前
jyy发布了新的文献求助200
2分钟前
2分钟前
灵巧孤菱完成签到,获得积分10
2分钟前
lurq发布了新的文献求助10
2分钟前
顾矜的应助被科研通管家采纳,获得10
2分钟前
KSDalton完成签到,获得积分10
2分钟前
丰富的大地完成签到,获得积分10
3分钟前
灵巧怀曼完成签到,获得积分10
3分钟前
廖道罡完成签到,获得积分10
4分钟前
liunahan完成签到 ,获得积分10
4分钟前
大气的湘完成签到,获得积分10
4分钟前
Cosmosurfer完成签到,获得积分0
5分钟前
飞哥与小佛完成签到,获得积分10
5分钟前
无私鹤轩完成签到,获得积分10
5分钟前
玫瑰555完成签到 ,获得积分10
5分钟前
历史真相完成签到,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195212
求助须知:如何正确求助?哪些是违规求助? 9580956
关于积分的说明 21873011
捐赠科研通 7795247
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561284
邀请新用户注册赠送积分活动 2484708